Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and have consistently replaced the previous dominant variant. Therapeutics against variants of SARS-CoV-2 are urgently needed. Ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wen, Zhang, Zherui, Zhu, Yuhe, Chen, Ben, Gu, Chunying, Liu, Zhiyan, Zhang, Xukai, Xiong, Hualong, Zhang, Yanan, Zheng, Bin, Wang, Rongjuan, Jiao, Shasha, Wang, An, Zhang, Tianying, Zhang, Jinchao, Wang, Shuang, Zhang, Bo, Li, Gang, Gui, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304585/
https://www.ncbi.nlm.nih.gov/pubmed/35873586
http://dx.doi.org/10.3389/fphar.2022.926750

Ejemplares similares

Ejemplares similares